# Plain RAG on Multiple mitochondrial dysfunctions syndrome 9B (FDXR, OMIM:620887)
model: gemini-3.8-flash   generated: 2026-09-28 20:48

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `FDXR gene Multiple mitochondrial dysfunctions syndrome 9B`

[1] **620887 - MULTIPLE MITOCHONDRIAL DYSFUNCTIONS ...**  
    https://omim.org/entry/620887  
    multiple mitochondrial dysfunctions syndrome-9B (MMDS9B) is caused by homozygous or compound heterozygous mutation in the FDXR gene (103270), ...

[2] **Multiple Mitochondrial Dysfunctions Syndrome 9b (MMDS9B)**  
    https://www.malacards.org/card/multiple_mitochondrial_dysfunctions_syndrome_9b  
    Multiple mitochondrial dysfunctions syndrome-9B (MMDS9B) is an autosomal recessive disorder characterized by optic atrophy and/or auditory neuropathy.

[3] **multiple mitochondrial dysfunctions syndrome 9B**  
    https://zfin.org/DOID:0070736  
    A multiple mitochondrial dysfunctions syndrome characterized by optic atrophy and/or auditory neuropathy variably associated with developmental delay

[4] **Multiple mitochondrial dysfunctions syndrome 9b (Concept Id**  
    https://www.ncbi.nlm.nih.gov/medgen/1860851  
    FDXR (17q25.1) is characterized by optic atrophy and/or auditory neuropathy variably associated with developmental delay or regression, global hypotonia,

[5] **FDXR**  
    https://panelapp.genomicsengland.co.uk/panels/genes/FDXR  
    Phenotypes Multiple mitochondrial dysfunctions syndrome 9B, in Likely inborn error of metabolism Level. FDXR in Possible mitochondrial disorder,

[6] **Submission Details**  
    https://thegencc.org/submissions/SGC-179637.1  
    FDXR was first reported in relation to optic atrophy in 2017, in patients with optic atrophy and auditory neuropathy (PMID: 28965846), and in 2018 in ...

## 2. The context handed to the model
```
[1] 620887 - MULTIPLE MITOCHONDRIAL DYSFUNCTIONS ...
https://omim.org/entry/620887
multiple mitochondrial dysfunctions syndrome-9B (MMDS9B) is caused by homozygous or compound heterozygous mutation in the FDXR gene (103270), ...

[2] Multiple Mitochondrial Dysfunctions Syndrome 9b (MMDS9B)
https://www.malacards.org/card/multiple_mitochondrial_dysfunctions_syndrome_9b
Multiple mitochondrial dysfunctions syndrome-9B (MMDS9B) is an autosomal recessive disorder characterized by optic atrophy and/or auditory neuropathy.

[3] multiple mitochondrial dysfunctions syndrome 9B
https://zfin.org/DOID:0070736
A multiple mitochondrial dysfunctions syndrome characterized by optic atrophy and/or auditory neuropathy variably associated with developmental delay

[4] Multiple mitochondrial dysfunctions syndrome 9b (Concept Id
https://www.ncbi.nlm.nih.gov/medgen/1860851
FDXR (17q25.1) is characterized by optic atrophy and/or auditory neuropathy variably associated with developmental delay or regression, global hypotonia,

[5] FDXR
https://panelapp.genomicsengland.co.uk/panels/genes/FDXR
Phenotypes Multiple mitochondrial dysfunctions syndrome 9B, in Likely inborn error of metabolism Level. FDXR in Possible mitochondrial disorder,

[6] Submission Details
https://thegencc.org/submissions/SGC-179637.1
FDXR was first reported in relation to optic atrophy in 2017, in patients with optic atrophy and auditory neuropathy (PMID: 28965846), and in 2018 in ...
```

## 3. The gene, from the sources

The *FDXR* gene is located at chromosomal position 17q25.1 and is associated with multiple mitochondrial dysfunctions syndrome-9B (MMDS9B) [4, 5]. The provided sources do not cover what the specific gene product of *FDXR* is or what specific mechanisms it performs within the cell, other than listing it under possible mitochondrial disorders and likely inborn errors of metabolism [5]. 

MMDS9B is an autosomal recessive condition caused by homozygous or compound heterozygous mutations in the *FDXR* gene [1, 2]. The link between *FDXR* variants and disease was first reported in 2017 in patients presenting with optic atrophy and auditory neuropathy [6]. Clinically, these mutations lead to MMDS9B, which is characterized by optic atrophy and/or auditory neuropathy variably accompanied by global hypotonia, developmental delay, or developmental regression [2, 3, 4].

*tokens in 503, out 1314*

## 4. The gene, closed book (no sources; beware hallucinations)

The ***FDXR*** gene encodes **ferredoxin reductase**, a mitochondrial flavoprotein that transfers electrons from NADPH to ferredoxins (FDX1 and FDX2). This electron transfer cascade is critical for the biogenesis of iron–sulfur (Fe–S) clusters, heme synthesis, and maintaining mitochondrial iron homeostasis.

Pathogenic variants reduce FDXR stability or catalytic activity, severely impairing Fe–S cluster synthesis. Because Fe–S clusters serve as essential prosthetic groups for respiratory chain complexes I, II, and III, their deficiency causes electron transport chain failure, reduced ATP production, and iron overload-induced reactive oxygen species (ROS) accumulation. This energy failure and oxidative stress selectively damage vulnerable tissues, leading to Multiple Mitochondrial Dysfunctions Syndrome manifestations such as optic atrophy, peripheral neuropathy, and progressive neurodegeneration.

This genetic disorder was first described in **2017**.

**Citation:**  
Slone, J., et al. (2017). *De Novo and Biallelic FDXR Mutations Cause a Novel Neurological Syndrome with Optic Atrophy, Retinitis Pigmentosa, and Axonal Neuropathy.* **American Journal of Human Genetics**, 101(5), 609–619. *(Published concurrently with Paul, A. et al., 2017).*

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P06)

Based on the provided sources, here is the clinical genetic evaluation:

### 1. Patient Evaluation (Rule-In / Rule-Out)

The sources define Multiple Mitochondrial Dysfunctions Syndrome 9B (MMDS9B) as being characterized by **optic atrophy and/or auditory neuropathy** [2, 3, 4, 6], variably associated with **developmental delay or regression** [3, 4] and **global hypotonia** [4]. 

* **P01**: **Cannot be ruled in; likely ruled out.** Lacks optic atrophy and auditory neuropathy, the defining cardinal features of MMDS9B [2, 3, 4]. However, the sources do not explicitly state negative exclusion criteria to definitively rule P01 out.
* **P02**: **Cannot be ruled in; unlikely.** P02 exhibits optic atrophy [2, 3, 4], but lacks the developmental delay, regression, or hypotonia mentioned in the sources [3, 4]. Furthermore, features such as CSF oligoclonal IgG bands and CNS demyelination are not mentioned in the sources [1–6].
* **P03**: **Cannot be ruled in; likely ruled out.** While P03 has hypotonia and developmental delay [3, 4], P03 lacks optic atrophy and auditory neuropathy, the defining cardinal features of MMDS9B [2, 3, 4].
* **P04**: **Cannot be ruled in; likely ruled out.** Has developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4].
* **P05**: **Cannot be ruled in; likely ruled out.** Has hypotonia and developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4].
* **P06**: **Most consistent (Rule-in candidate).** P06 possesses the primary defining feature—**optic atrophy** [2, 3, 4, 6]—along with **developmental delay**, **developmental regression**, and **hypotonia**, which are explicitly cited as associated features of MMDS9B caused by *FDXR* mutations [3, 4]. 
* **P07**: **Cannot be ruled in; likely ruled out.** Has developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4].
* **P08**: **Cannot be ruled in; likely ruled out.** Has hypotonia [4], but lacks optic atrophy and auditory neuropathy [2, 3, 4].
* **P09**: **Cannot be ruled in; likely ruled out.** Has developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4].
* **P10**: **Cannot be ruled in; likely ruled out.** Lacks optic atrophy, auditory neuropathy, hypotonia, developmental delay, and regression [2, 3, 4].

*(Note: The sources do not provide an exhaustive phenotypic spectrum or mandatory exclusion criteria [1–6]; thus, no patient can be definitively ruled out on clinical grounds alone using only the provided text).*

---

### 2. Single Most Likely Patient and Probability

* **Most likely patient**: **P06**
* **Estimated probability**: **~90–95%** (given the premise that exactly one of the 10 patients has MMDS9B). 
  * *Reasoning*: P06 is the only patient presenting with both the core defining feature (**optic atrophy**) [2, 3, 4, 6] and the full triad of described associated features (**global developmental delay**, **developmental regression**, and **hypotonia**) [3, 4]. P02 has optic atrophy [2, 3, 4] but lacks any of the other characteristic features and has findings indicative of demyelinating disease not mentioned in the sources.

---

### 3. Facts Needed to Be Confident (Not in the Sources)

To confirm MMDS9B with clinical and diagnostic certainty, the following information is required:
1. **Molecular genetic confirmation**: Demonstration of pathogenic homozygous or compound heterozygous variants in the *FDXR* gene [1].
2. **Audiological assessment**: Presence or absence of auditory neuropathy [2, 3, 4, 6].
3. **Exclusionary criteria / Full phenotypic spectrum**: Complete clinical details clarifying whether respiratory failure, seizures, or specific brain MRI findings (seen in P06) are documented features of MMDS9B, as the provided sources do not mention these features [1–6].

--------------------------------------------------------------------------------

### Round 2  (picked: P06)

Based on the provided sources, here is the clinical genetic assessment:

### 1. Patient Evaluation (Rule-in / Rule-out)

The provided sources define multiple mitochondrial dysfunctions syndrome 9B (MMDS9B) as an autosomal recessive disorder characterized by optic atrophy and/or auditory neuropathy, variably associated with developmental delay or regression and global hypotonia [2, 3, 4, 6]. The sources do not provide comprehensive lists of non-core features or negative exclusion rules [1–6].

* **P01:** **Cannot rule in / Unlikely.** Lacks the core characterizing features of optic atrophy and auditory neuropathy [2, 3, 4, 6]. However, the sources do not provide negative exclusion criteria to strictly rule this patient out [1–6].
* **P02:** **Cannot rule in / Unlikely.** Has optic atrophy [2, 3, 4, 6], but lacks the associated features documented in the sources (developmental delay, regression, hypotonia) [3, 4]. Features such as CSF oligoclonal IgG bands and CNS demyelination are not mentioned in the sources [1–6].
* **P03:** **Cannot rule in / Unlikely.** Lacks optic atrophy and auditory neuropathy [2, 3, 4, 6]. The sources do not provide definitive exclusion criteria [1–6].
* **P04:** **Cannot rule in / Unlikely.** Lacks optic atrophy and auditory neuropathy [2, 3, 4, 6]. The sources do not provide definitive exclusion criteria [1–6].
* **P05:** **Cannot rule in / Unlikely.** Has hypotonia and developmental delay [3, 4], but lacks the cardinal features of optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P06:** **Most consistent / Strongest candidate.** Features optic atrophy [2, 3, 4, 6], global developmental delay [3, 4], developmental regression [4], and hypotonia [4]. The sources do not state whether features like respiratory failure, seizures, or brain MRI abnormalities occur in MMDS9B, so these cannot be confirmed or refuted by the text [1–6].
* **P07:** **Cannot rule in / Unlikely.** Lacks optic atrophy and auditory neuropathy [2, 3, 4, 6]. 
* **P08:** **Cannot rule in / Unlikely.** Has hypotonia [4], but lacks optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P09:** **Cannot rule in / Unlikely.** Lacks optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P10:** **Cannot rule in / Unlikely.** Lacks optic atrophy, auditory neuropathy, developmental delay, regression, and hypotonia [2, 3, 4, 6].

---

### 2. Single Most Likely Patient and Probability

* **Most likely patient:** **P06**
* **Estimated probability:** **~85–90%**
  * *Rationale:* Exactly one patient among the 10 is stated to have MMDS9B. Only P02 and P06 possess the cardinal clinical sign of optic atrophy [2, 3, 4, 6]. Between the two, P06 demonstrates the full spectrum of secondary features specified in the sources: global developmental delay [3, 4], developmental regression [4], and hypotonia [4]. P02 has an adult-onset neuroinflammatory profile (CNS demyelination, CSF oligoclonal IgG bands) not described in the sources [1–6]. The probability is not 100% because the sources do not provide full phenotypic spectra or confirm whether severe systemic features (ventilator dependence, apnea) occur in MMDS9B [1–6].

---

### 3. Missing Information Needed for Diagnostic Certainty

To achieve diagnostic certainty, the following information—absent from the provided sources—would be required:
1. **Molecular genetic data:** Demonstration of homozygous or compound heterozygous pathogenic variants in *FDXR* [1].
2. **Auditory status:** Confirmation of whether auditory neuropathy (a cardinal feature in [2, 3, 4, 6]) is present or absent in P06.
3. **Comprehensive phenotypic spectrum:** The sources do not specify whether the following findings present in P06 are part of the MMDS9B phenotype:
   * Respiratory failure, apnea, and ventilator dependence [1–6]
   * Seizures [1–6]
   * Structural or diffusion brain MRI findings (cerebral cortical atrophy, corpus callosum abnormalities) [1–6]
   * Dysphagia / gastrostomy dependence [1–6]

--------------------------------------------------------------------------------

### Round 3  (picked: P06)

### 1. Evaluation of Each Patient (Ruling In/Out)

The sources establish that Multiple Mitochondrial Dysfunctions Syndrome 9B (MMDS9B) is characterized by **optic atrophy and/or auditory neuropathy**, variably associated with **developmental delay or regression** and **global hypotonia** [2, 3, 4, 6], and is caused by homozygous or compound heterozygous mutations in *FDXR* [1]. 

*The sources do not provide complete clinical inclusion/exclusion criteria or genetic testing for these individuals, so no patient can be definitively ruled in or ruled out with absolute certainty on clinical features alone [1, 4].* However, based on the defining features provided:

* **P01:** **Cannot be ruled in; likely ruled out.** Lacks optic atrophy and auditory neuropathy, which are the cardinal defining features of MMDS9B [2, 3, 4, 6].
* **P02:** **Cannot be ruled in or definitively ruled out.** Possesses optic atrophy [2, 3, 4, 6], but lacks the developmental delay, developmental regression, or global hypotonia noted in the sources [3, 4]. Furthermore, features such as CSF oligoclonal IgG bands and CNS demyelination are not mentioned in the sources.
* **P03:** **Cannot be ruled in; likely ruled out.** Has axial hypotonia and severe global developmental delay [3, 4], but lacks the defining features of optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P04:** **Cannot be ruled in; likely ruled out.** Has global developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P05:** **Cannot be ruled in; likely ruled out.** Features hypotonia and global developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P06:** **Most consistent; cannot be definitively ruled in without genetics.** Possesses optic atrophy [2, 3, 4, 6] as well as global developmental delay, developmental regression, and hypotonia [3, 4]. Other listed features (e.g., respiratory failure, seizures, MRI abnormalities) are neither confirmed nor excluded by the brief text in the sources.
* **P07:** **Cannot be ruled in; likely ruled out.** Has global developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P08:** **Cannot be ruled in; likely ruled out.** Has hypotonia [4], but lacks optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P09:** **Cannot be ruled in; likely ruled out.** Has global developmental delay [3, 4], but lacks optic atrophy and auditory neuropathy [2, 3, 4, 6].
* **P10:** **Cannot be ruled in; likely ruled out.** Features no cardinal or associated manifestations of MMDS9B described in the sources [2, 3, 4, 6].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient:** **P06**
* **Estimated Probability:** **~90%**  
  *Rationale:* The condition is defined by optic atrophy and/or auditory neuropathy [2, 3, 4, 6] with variable developmental delay/regression and global hypotonia [3, 4]. Only P02 and P06 have optic atrophy; of these, only P06 exhibits the associated developmental delay, regression, and hypotonia [3, 4]. P02 has an inflammatory demyelinating profile (CSF oligoclonal bands, CNS demyelination) not indicated by the sources.

---

### 3. Missing Facts Needed for Confidence

To establish a definitive diagnosis, the following information (not provided in the sources or patient descriptions) would be required:
1. **Molecular Genetic Testing:** Confirmation of biallelic (homozygous or compound heterozygous) pathogenic variants in the *FDXR* gene [1].
2. **Audiological Assessment:** Objective evaluation for auditory neuropathy (e.g., auditory brainstem response testing), which is a cardinal manifestation of the disorder [2, 3, 4, 6].
3. **Comprehensive Phenotypic Spectrum:** The provided sources do not detail the full spectrum of systemic and neuroimaging findings (such as whether respiratory failure, seizures, or specific brain MRI findings occur in MMDS9B) [1–6].

--------------------------------------------------------------------------------

picks across rounds: ['P06', 'P06', 'P06']
